[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cara Spence\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100605250",false,"NCT07160075","HIV Prevention With PrEP Among People on Opioid Replacement Therapy","Improving Access to HIV Pre-exposure Prophylaxis: Implementation and Evaluation of Innovative HIV Prevention Services Among Persons on Opioid Replacement Therapy in Western Canada: Prospective, Implementation Study","OAT-PrEP","Inclusion Criteria:\n\n* HIV negative\n* Ongoing behaviors with potential HIV exposure as assessed by a clinician\n* Regularly engaged with their respective OAT program at least 3 days a week for the past 2 weeks\n* Report willingness to return for follow-up visits\n\nExclusion Criteria:\n\n* Creatine clearance \\\u003C30 mL\u002Fmin or any medical condition or medication known to be contraindicated with the use of Emtricitabine\u002FTenofovir Alafenamide (F\u002FTAF) or Emtricitabine\u002FTenofovir Disoproxil Fumarate (F\u002FTDF)\n* Taken PrEP within the last 24 hours at the time of screening or enrollment\n* Deemed appropriate by a clinician for HIV Post-Exposure Prophylaxis at the time of screening or enrollment",true,"ALL","16 Years",{"count":20,"type":21},350,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based programs operating in Alberta and Saskatchewan, to collect preference, adherence, and persistence data on oral PrEP, and to assess interest \u002F acceptability of long-lasting injectable options for human immunodeficiency virus (HIV) prevention.",[27],"HIV - Human Immunodeficiency Virus",[29,30,31,32],"PrEP","OAT","Opioid Agonist Therapy","HIV","RECRUITING","2025-10-01",{"date":36,"type":37},"2025-10-07","ACTUAL",{"date":39,"type":37},"2025-08-28",{"date":41,"type":21},"2027-09-01",{"name":43,"class":44},"Cara Spence","OTHER",6,""]